GLP1R and prostate carcinoma: Previous studies on cell lines showed that GLP-1 receptor agonists inhibit signaling pathways engaged in tumorigenesis of prostate cancer through the suppression of proliferation and increase apoptosis of human prostate cancer cells [28,61].